Speakers: Laurence Fayadat-Dilman (Merck and Co), Keegan Cooke (Amgen), Jay Tibbitts (Surrozen), Robert Caldwell (AbbVie), Lilia Koriazova (Erasca), Sara Glickstein Bar-Zeev (Genentech); Key Kang (Genentech), Arianne L. Motter (FDA)
Organizers: Ayse Meric Ovacik (Genentech); Smita Salian-Mehta (Gilead); Isabel Figueroa Amenabar (Amgen); Laurence Fayadat-Dilman (Merck and Co); Minli Xie (Erasca); Snow Ge (Biobridge Pharma); Shichang Miao (Amgen)
Date: 2023-05-24
Time: 8:45-17:25 Pacific Time
Registration fee: Regular attendees: $295; Academic/Students/Postdocs: $125; Major Sponsorship: $3000; Vendor Show: $695; On-site Registration:$500
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor: (2).; Veloxity Labs
Vendor show vendors registered to date: (23)Abzena; Alturas Analytics; Biointron; BioTether Sciences; Charles River Labs; CHIRON Recombinant Proteins; Correlia Biosystems Inc; CP Lab Safety; Ellegaard BioResearch; Emery Pharma; Frontage Laboratories; Gator Bio; GBI Bio; Inotiv; IRBM; KCAS Bio; Meadowhawk Biolabs; Medicilon; MilliporeSigma; Novogene Corporation Inc.; Q2Lab Solutions; QPS LLC; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2023-05-23  (it will close sooner if the seating cap is reached)

About the Topic

Commercial clinical pipeline of mAbs has vastly increased in recent years; the mAbs based therapeutics in development has been growing at an incredible pace. The investigational new drug application (IND) application is an important step to achieve in mAb based therapeutics, and understanding the requirements for a successful IND filing is utmost important to ensure fast and efficient development. While the principles and basics are similar across different modalities for an IND filing such as safety studies, there are important aspects that need to be considered for mAb based therapeutics. In this workshop, we will cover the best practices for a successful IND package of mAbs. Our highly experienced speakers will discuss the preclinical studies for mAb based therapeutics IND packages. This workshop will be suitable for novice drug developers and small molecule drug development experts who are interested in mAb therapeutic development.

Topics to be covered:

• Overview of preclinical development and IND filing requirements for antibody-based therapeutics
• Required preclinical studies for
  Safety assessment
  Pharmacology
  Pharmacokinetics
  CMC (Chemistry, Manufacturing, Control)
• Clinical development plans
• FDA’s perspective by an FDA reviewer